Antisense Oligonucleotide definition

Antisense Oligonucleotide means a polynucleotide, oligonucleotide, or oligonucleotide analog, which hybridizes in a sequence specific manner under physiological conditions to RNA forming an RNA-DNA duplex, which duplex acts to modulate the production of a targeted gene product. An antisense oligonucleotide analog may include naturally occurring or non-natural heterocycles, sugar and/or backbone linkages, and may be a molecule in which the sugar may be absent, in which the backbone linkage may be phosphate based, amide based, or based on other chemistries and which may or may not include stem loop or structural units.
View Source
Antisense Oligonucleotide means a technology that utilizes [***].
View Source
Antisense Oligonucleotide or “ASO” means an RNA construct (modified or unmodified), including the sequence of such construct and the chemistry of natural and non-natural nucleic acids contained in such construct and the other chemical elements contained in such construct.
View Source

Examples of Antisense Oligonucleotide in a sentence

  • Such Cooperative Efficacy Criteria shall include the amount of each Arena Antisense Oligonucleotide and Arena Missense Oligonucleotide required by Fujisawa to conduct such in vivo analysis, and shall be attached hereto as EXHIBIT B and shall form a complete part of this Agreement.

  • In the event that the Arena Antisense Oligonucleotide does not meet the Cooperative Efficacy Criteria, then all data developed by Fujisawa thereon ("Non-Success Data") shall be transferred to Arena within one (1) month of the date of such Non-Success Notice, and all such Non-Success Data shall be owned exclusively, even as to Fujisawa, by Arena.

  • In the event that the Arena Antisense Oligonucleotide meets the Cooperative Efficacy Criteria, then the Parties acknowledge and agree that the provisions of Article III shall automatically begin with respect to the Arena ************** Orphan Receptor corresponding to such Arena Antisense Oligonucleotide.

  • Subject to the provisions contained in paragraphs in 2.4, 4.4 and 4.5 hereunder, the invoice price for Quantification Oligonucleotides (and/or Antisense Oligonucleotide) prior to application of Customer Deposit shall be [***] of the IDT List Price for corresponding oligonucleotide Primers and/or Probes and the associated purification, analytical and/or set-up fees.

  • It is agreed that one purpose of the Joint Patent Subcommittee is to ensure that each Party shall take into account in good faith any good faith comments by the other Party as to the scope of any claims pursued in any Patent Rights directed to specific Stereochemically Pure ssRNAi or Antisense Oligonucleotide drug candidates Developed for the relevant Pfizer Program or Wave Program.

  • Wave will use Commercially Reasonable Efforts to research and Develop at least one (1) Stereochemically Pure ssRNAi or Antisense Oligonucleotide drug candidate through the CAN Stage (the “Candidate Compound”) for each Pfizer Program (including alternate Pfizer Programs further to Section 4.1.5), according to the efforts described in the Research Plan.

  • Subject to Section 4.1.6, Wave will have the right (but not the obligation) to designate therapeutic targets for stereochemically controlled Oligonucleotide therapies involving ssRNAi or Antisense Oligonucleotide (or any combination thereof) applications only for research, Development and Commercialization, incorporating Pfizer Technology, under the terms and conditions of this Agreement (each, a “Wave Program”).